Bringing the fundamentals into focus…
Back to Recursion Pharmaceuticals, Inc.
How Recursion Pharmaceuticals, Inc. stacks up
RXRX · against 1,216 other Healthcare companies
Growth
17/ 100
Near the bottom of its peers.
Ranked #1,005 of 1,217 · scores higher than 17% of peers
Bars: peers in each 10-point band of the growth score122 peers with a growth score of 10–19, including RXRX · Click a bar to see the companies
Why growth scores 17?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 88% of peers. Revenue growth: -15.1% vs peer median 6.1%
- slower revenue growth over three years: weaker than 61% of peers. 3-year revenue growth: 3.1% vs peer median 5.8%
- Earnings per share growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = RXRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RXRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | -15.1% | 6.1% | 12% | 33% | |
| Earnings per share growthHigher is better · 682 reported | Not reported | 9.7% | — | — | 33% |
| 3-year revenue growthHigher is better · 1,192 reported | 3.1% | 5.8% | 39% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around RXRXScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score